ChemoMetec Sees Substantial Revenue Growth in Q1 2025/26
In the recent trading update for the first quarter of 2025/26, ChemoMetec demonstrated remarkable performance with an 8% increase in revenue, reaching DKK 124.6 million compared to DKK 115.6 million during the same period last year. This includes an impressive 11% growth when adjusting for constant exchange rates, highlighting the company’s strong market presence and the increasing demand for its innovative solutions.
Strong Demand for Instruments and Services
The growth trajectory is supported by robust sales across a broad spectrum of products including instruments, consumables, and services. Notably, the sales of instruments increased by 4% to DKK 40.7 million, reflecting stable performance of both XcytoMatic and NucleoCounter instrument lines. Furthermore, sales related to consumables surged by 12%, while service revenue reported a 4% growth. This substantiates ChemoMetec's commitment to providing high-quality solutions that meet evolving customer needs.
EBITDA and Operational Performance
ChemoMetec's EBITDA rose to DKK 68.8 million, marking an 11% increase from DKK 62.1 million in the previous year, with an EBITDA margin expanding to 55%. This increase is attributed to effective cost management and a growing portfolio of high-margin products. The favorable financial results position the company well for future growth opportunities within its core sectors.
Product Development Initiatives
The development pipeline remains strong with key projects, including the XcytoMatic 50 and the Sample Management System, which are progressing as planned. ChemoMetec emphasizes continuous improvement through consistent and constructive feedback from customers, leading to innovations that align with industry trends. This forward-thinking approach was showcased at a significant conference where product advancements were well received, further enhancing the company's market standing.
Challenges in the Market
Despite the positive outlook, ChemoMetec noted some challenges due to geopolitical uncertainties affecting customer sentiment, particularly in cell therapy sectors. Some major players expressed reluctance to expand operations due to rising production costs. Nonetheless, demand for cell and gene therapy solutions remains firm, focusing on cost reduction strategies that align with automation — an area where ChemoMetec’s instruments are poised to deliver substantial benefits.
Geographical Revenue Breakdown
The revenue performance varied across regions, with the USA/Canada market achieving a 4% increase in Q1, supported by consistent demand for instruments and consumables. Conversely, European revenue experienced significant growth of 18%, driven primarily by a 33% increase in consumables, underscoring the strategic importance of this market to ChemoMetec’s overall success.
Maintaining Revenue Guidance Amidst Growth
ChemoMetec is steadfast in its revenue and EBITDA guidance for the fiscal year 2025/26, maintaining targets of DKK 565-580 million and DKK 320-335 million respectively. This consistency reflects the company’s confidence in its operational strategy and growth trajectory in both existing and emerging markets.
About ChemoMetec A/S
Founded in 1997, ChemoMetec develops, manufactures, and markets advanced instruments for cell counting and various measurement applications. The company serves clients in the pharmaceutical, biotechnology, and agricultural sectors, including leading global pharmaceutical firms. Being listed on Nasdaq OMX Copenhagen, ChemoMetec is committed to excellence in its field.
Frequently Asked Questions
What are the key financial highlights for Q1 2025/26?
ChemoMetec reported an 8% revenue increase to DKK 124.6 million and an EBITDA growth to DKK 68.8 million, reflecting strong operational performance.
How did ChemoMetec achieve revenue growth?
The revenue growth was driven by increased sales in instruments, consumables, and services, indicating a strong market demand for the company's products.
What products contributed to ChemoMetec’s success?
Sales of both XcytoMatic and NucleoCounter instruments, as well as consumables, were significant contributors to the positive results.
What is the company’s guidance for the remainder of 2025/26?
ChemoMetec maintains its revenue guidance within the range of DKK 565-580 million and EBITDA expectations of DKK 320-335 million for the fiscal year.
How does ChemoMetec plan to address market challenges?
Despite geopolitical uncertainties, ChemoMetec focuses on automation in cell and gene therapy production, aligning its solutions to improve efficiency and reduce costs for customers.
